Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through Contract Research Services and Research Products segments. The Contract Research Services segment offers screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing services. It also provides in vivo sampling services for the continuous monitoring of chemical changes in life; preclinical and pathology services; product characterization, method development, and validation; bioanalytical testing to measure drug and metabolite concentrations in complex biological matrices; stability testing to establish and confirm product purity, potency, and shelf life; and climate-controlled archiving services for its customers' data and samples. The Research Products segment offers analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments; and Vetronics' products, such as instruments and related software to monitor and diagnose cardiac function, and measure other vital physiological parameters in cats and dogs in veterinary clinics. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BASI
CUSIPN/A
Phone765-463-4527
Debt
Debt-to-Equity Ratio0.47
Current Ratio0.73
Quick Ratio0.62
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$24.24 million
Price / Sales0.69
Cash Flow$0.3184 per share
Price / Cash5.15
Book Value$0.90 per share
Price / Book1.82
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$880,000.00
Net Margins1.06%
Return on Equity4.43%
Return on Assets1.66%
Miscellaneous
Employees155
Outstanding Shares10,240,000
Market Cap$16.39 million
Bioanalytical Systems (NASDAQ:BASI) Frequently Asked Questions
What is Bioanalytical Systems' stock symbol?
Bioanalytical Systems trades on the NASDAQ under the ticker symbol "BASI."
How were Bioanalytical Systems' earnings last quarter?
Bioanalytical Systems, Inc. (NASDAQ:BASI) issued its quarterly earnings data on Thursday, August, 11th. The company reported ($0.05) earnings per share for the quarter. The business had revenue of $5.05 million for the quarter, compared to analyst estimates of $6.15 million. Bioanalytical Systems had a net margin of 1.06% and a return on equity of 4.43%. View Bioanalytical Systems' Earnings History.
When is Bioanalytical Systems' next earnings date?
Who are some of Bioanalytical Systems' key competitors?
Some companies that are related to Bioanalytical Systems include Senomyx (SNMX), Dyadic International, Inc common stock (DYAI), Vitality Biopharma (VBIO), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), Protalex (PRTX), US Stem Cell (USRM), Tenax Therapeutics (TENX), Geovax Labs (GOVX), ALGAE TEC Ltd/S (ALGXY) and Redpoint Bio (RPBC).
Who are Bioanalytical Systems' key executives?
Bioanalytical Systems' management team includes the folowing people:
- Mr. Philip A. Downing, Acting Principal Exec. Officer & Sr. VP of Preclinical Services (Age 48)
- Ms. Jill C. Blumhoff, Principal Accounting Officer, CFO & VP of Fin. (Age 42)
- Dr. Peter T. Kissinger, Founder, Chairman Emeritus and Scientific Advisor (Age 73)
- Ms. Erica Wasson, Director of HR
- Ms. Stephanie Miller, Director of Client Services
Has Bioanalytical Systems been receiving favorable news coverage?
Press coverage about BASI stock has trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bioanalytical Systems earned a media and rumor sentiment score of 0.16 on Accern's scale. They also assigned news articles about the company an impact score of 45.51 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Bioanalytical Systems.
How do I buy shares of Bioanalytical Systems?
Shares of BASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bioanalytical Systems' stock price today?
One share of BASI stock can currently be purchased for approximately $1.64.
How big of a company is Bioanalytical Systems?
Bioanalytical Systems has a market capitalization of $16.39 million and generates $24.24 million in revenue each year. Bioanalytical Systems employs 155 workers across the globe.
How can I contact Bioanalytical Systems?
Bioanalytical Systems' mailing address is 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906. The company can be reached via phone at 765-463-4527 or via email at [email protected]
MarketBeat Community Rating for Bioanalytical Systems (NASDAQ BASI)
MarketBeat's community ratings are surveys of what our community members think about Bioanalytical Systems and other stocks. Vote "Outperform" if you believe BASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
